Page 858 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

836 Index

Radiation therapy (RT) (Continued) Radiopharmaceuticals, for primary and Relationship-centered communication,
310–311
metastatic bone cancer pain, 547–548
cell sensitivity to, 210 Radiosensitization, 183 Relationship-centered visit, 311
chemical modifiers of, 213
VetBooks.ir computed tomography versus, 113 Radiosensitizer, 213 Relative biologic effectiveness (RBE),
for cutaneous feline mast cell tumor, 395
Radium (226R), 524–525
210–211
for digital malignant melanoma, 362 Raleigh chromosome, 11–12 Relative risk (RR)
DNA damage from, 209–210 Randomization, 344 calculation of, 86
effects of Randomized control trial (RCT) interpretation of, 86, 86t
acute, 212 definition of, 82t Renal cancer, 653
late, 212 design of, 344–345 Renal carcinoma, 135
to normal tissues, 212–213 limitations of, 93–94 Renal cyst, nodular dermatofibrosis and, 104
equipment, 215–218 Randomized discontinuation trial, 347 Renal cystadenocarcinoma/nodular
for feline acromegaly, 571 Rapamycin, 262 dermatofibrosis (RCND), 354, 360
for feline sarcomas, 421–423 Ras, 42 Renal lymphoma, 652
“four Rs” of, 211 Ras proto-oncogene, 42 Renal manifestation, of cancer
fractionation, 211–215 RAS signal transduction, 259f glomerulonephritis as, 99b, 106
for gross disease, 415–416 RAS-RAF-MEK-ERK/p38/JNK miscellaneous syndromes of, 106
immobilization and localization techniques, family, 258 Renal tumor
218 RB gene abnormalities, canine osteosarcoma canine, 652–653
immunotherapy and, 242–243 and, 525 feline, 653
for intestinal tumor, 467 RBE. see Relative biologic effectiveness laboratory findings for, 652
for intracranial tumors, 664–665 RCND. see Renal cystadenocarcinoma/ metastasis of, 652–653
length of time for, 211–212 nodular dermatofibrosis signs of, 652
lymphoma, 223–224 RCT. see Randomized control trial staging of, 652
megavoltage photons and, 209 Reactive fibroblast, 63 Reoxygenation, cell cycle and, 211
for nasal planum SCC, 357 Reactive histiocytosis, 794 Replication-competent viral vector, 254
nutritional support during, 309 Reactive oxygen species (ROS), 210 Replicative senescence, 46
for oral melanoma, 370–374, 373f–374f Reactive papilloma, 675 Repopulation
with chemotherapy, 374–376 Real-time PCR, 151–153, 152f of proliferating normal tissues, 212
published studies for, 372t–373t Recepteur d’origine Nantaise (RON), 533 of tumor cells, 211
for oral tumors, 437–440 Receptor tyrosine kinase (RTK), 258 Report on Carcinogens (RoC), 13–14
for orbit and optic nerve tumors, 684 Geldanamycin targeting, 271 Reproductive system tumor
for pain management, 297–298 malignancies and, 258f female, 604–625
planning and delivery techniques, 215–216, Receptor tyrosine kinase inhibitors, for gross male, 626–644
217t osteosarcoma, 546 RER. see Resting energy requirement
principles of, 209–211 Receptor tyrosine kinase (RTK) signaling Rescue therapy, 183
role in advanced cancer, 209 cyclin-dependent kinases and, 259 Reserve cell, 134f
for soft tissue sarcomas, 413–415, 414t, cytoplasmic kinases and, 258 Respiratory quotient (RQ), 300
415f importance of, 258 Respiratory system, tumors of, 492–523
for spinal cord tumors, 668–669 RECIST. see Response evaluation criteria in nasal planum, cancer of, 492
surgery and, 170 solid tumors Response evaluation criteria in solid
surviving fraction of cells and, 214 Recombinant cytokine therapy, tumors (RECIST), with cytotoxic
tumors commonly treated with, 218–224 immunotherapy using, 237–238 chemotherapeutics, 342–343
bone, 222–224 interleukin-2, 237–238 Resting energy expenditure (REE), 300
cranial vault, 220–221 interleukin-12, 238 Resting energy requirement (RER), 304
nasal, 219–220 interleukin-15, 238 Restriction point (R), 36
oral, 218–219 Recurrent laryngeal nerves, 576 Retinoblastoma (RB)
trunk and extremities, 221–222 Red blood cell canine osteosarcoma and, 525
ultrasonography versus, 113–114 anemia of chronic disease and, 102 form of, 43
wound healing and, 170 blood loss anemia and, 102 tumor suppressor genes and, 43
Radiation-induced neoplasia, 212 shearing, 103 Retinoic acid, 309
criteria for, 213 Redistribution, cell cycle and, 211 13-cis-retinoic acid, 357
incidence of, 213 REE. see Resting energy expenditure Retinoic acid, for canine pituitary-dependent
Radical wound margin, 167t Refractory hypercalcemia of malignancy, hypercortisolism, 567
Radioactive iodine ( 131 I) 100–101 Retroviral life cycle, 251
for feline hyperthyroidism, 579–580 Registration trial, 345 Retroviral vector, 252f
for thyroid gland neoplasia, 577 Regulatory T cells (Tregs), in canine Retrovirus, 22
Radioactive isotope, 215 osteosarcoma, 534 core genes in, 41
Radiofrequency ablation, 169 Relationship-centered care, 311–312 DNA transfer to cells, 251
Radioisotopes, for canine osteosarcoma, 542 euthanasia discussions and, 312 feline leukemia virus as, 22
Radiology, in canine osteosarcoma, 528–529 frameworks for, 311 oncovirus versus lentivirus, 252t
Radionuclide, 241 outcomes for, 312 Reverse transcriptase inhibitor, 24